A large electronic health record study suggests that difficulty recognizing painless blood in urine may delay diagnosis and worsen long-term survival for bladder cancer patients with color vision ...
Also Read: ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug Specific key efficacy findings from cohort B (N=80) of the Phase 2/3 open-label, single-arm ...
Real-world effectiveness and treatment patterns in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in Japan: Long term follow-up from the ...
Bladder cancer (BCa), a common type of urothelial carcinoma in the urinary system, ranks as the tenth most prevalent malignancy worldwide and remains one of the leading causes of cancer-related ...
Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill ...
Bladder cancer is a highly prevalent disease in the Western World, and the treatment paradigm is actively evolving. For decades, the most commonly used standard of care for localized muscle-invasive ...
ImmunityBio's Anktiva helped 92.2% of evaluated patients avoid a cystectomy at 12 months post-treatment, the company reported. (peterschreiber.media/iStock/Getty ...
Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder cancer compared with those who can see colors. The researchers hypothesized ...
Researchers say approach could be useful for both initial treatment of bladder cancer as well as treatment refractory subsets of tumors.
WASHINGTON -- Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete response (CR) in more than 90% of patients who had refused cystectomy for high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results